Kamada (KMDA) has been awarded an extension of an existing tender from the Canadian Blood Services for the supply of four specialty plasma-derived products, WINRHO, HEPAGAM, CYTOGAM, and VARIZIG, for an additional two years. Valued at a range of $10M-$14M, the award secures ongoing sales of those products in the Canadian market between Q2-26 and Q1-28. The four commercial products are approved by Health Canada and the U.S. Food and Drug Administration. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMDA:
- Kamada Ltd. Shareholders Approve Key Resolutions at Annual Meeting
- Kamada price target raised to $13 from $11 at H.C. Wainwright
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.
- Kamada Discontinues Phase 3 Inhaled AAT Trial, Projects Growth in 2026
- Kamada discontinues Phase 3 inhaled AAT clinical trial